Skip to main content

Market Overview

GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial

Share:
GlycoMimetics Falls 50% After Disappointing Results For Sickle Cell Drug Trial

GlycoMimetics (NASDAQ: GLYC) announced late Friday afternoon that Pfizer's (NYSE: PFE) Phase 3 clinical trial evaluating Rivipansel in sickle cell disease has not met its primary or key secondary endpoints.

On Monday morning, a number of firms have downgraded the stock:

  • Jefferies downgraded the stock from Buy to Hold.
  • SunTrust Robinson Humphrey downgraded from Buy to Hold and lowered the price target from $23 to $5.
  • Piper Jaffray downgraded from Overweight to Neutral and lowered the price target from $20 to $6.

GlycoMimetics shares were trading down 51.81% at $4.40 in Monday’s pre-market session. The stock has a 52-week high of $17.07 and a 52-week low of $8.29.

Related Links:

The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA

 

Related Articles (GLYC)

View Comments and Join the Discussion!

Posted-In: Rivipansel sickle cellNews Health Care Top Stories Movers Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com